Jan 4, 2021
A randomized, multicenter, adaptive, double-blind,
placebo-controlled trial to evaluate whether the combination of
baricitinib plus remdesivir was superior to remdesivir alone.
Season-3 is here! Tune in for InpharmD's podcast series, as we bring you clinical summaries and critiques of the most trending medical literature on the market.
Having trouble logging in?